semaglutide cardiovascular risk outcomes align more closely with attained dose than achieved weight loss Cardiovascular outcomes of semaglutide and

TRIUMPH-4's 28.7% average is approaching sleeve gastrectomy territory (2530%)

Adults who may be considered for GLP-1 weight loss treatment often include those who: Have a body mass index (BMI) in the overweight or obese range Have struggled to lose weight through diet and exercise alone Have related conditions such as prediabetes, insulin resistance, or metabolic syndrome Are looking for a medically supervised approach to weight management Eligibility is determined by a licensed medical provider after reviewing your health history, current medications, and overall goals

The men werent more active and didnt burn more calories

10.1016/S0140-6736(85)91481-3

In individuals with AD, GLP-1RAs did not exert disease-modifying effects on cognition

[2023-07-04] 7